Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Overall Response Rate”

60 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 60 results

Not applicableNot Yet RecruitingNCT07542912
What this trial is testing

Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma

Who this might be right for
Complete Remission Rate， CRRProgression Free SurvivalOverall Survival+2 more
Sun Yat-sen University 30
Testing effectiveness (Phase 2)Study completedNCT00699881
What this trial is testing

Study of Cetuximab to Treat Gastric Cancer

Who this might be right for
Gastric Cancer
Fudan University 61
Not applicableLooking for participantsNCT06277024
What this trial is testing

A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients

Who this might be right for
Overall Response Rate
Fujian Medical University 50
Testing effectiveness (Phase 2)Ended earlyNCT02008006
What this trial is testing

BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT)

Who this might be right for
Follicular Lymphoma
Centre Leon Berard 21
Not applicableStudy completedNCT04902560
What this trial is testing

Response Rate to Ceftriaxone 1g IM in Gonorrhoea : a French Retrospective Monocentric Study

Who this might be right for
Gonorrhea
University Hospital, Montpellier 120
Not applicableStudy completedNCT01291667
What this trial is testing

Study for HER2-Overexpressed MBC Patients Treated by Cipterbin® Plus vinorelbinE

Who this might be right for
Progress-free SurvivalOverall Response RateAdverse Events
Shanghai CP Guojian Pharmaceutical Co., Ltd. 330
Testing effectiveness (Phase 2)Study completedNCT05114746
What this trial is testing

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 94
Testing effectiveness (Phase 2)Study completedNCT04350190
What this trial is testing

Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Who this might be right for
Nasopharyngeal Carcinoma
Wei Jiang 25
Large-scale testing (Phase 3)Study completedNCT00970138
What this trial is testing

Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer

Who this might be right for
Gastric Carcinoma
Fudan University 141
Testing effectiveness (Phase 2)Study completedNCT02383498
What this trial is testing

QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma

Who this might be right for
Chordoma
NantCell, Inc. 24
Testing effectiveness (Phase 2)UnknownNCT04102982
What this trial is testing

Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer

Who this might be right for
NSCLC Stage IV
Shandong Provincial Hospital 200
Testing effectiveness (Phase 2)Study completedNCT05670106
What this trial is testing

Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 62
Early research (Phase 1)Looking for participantsNCT07238075
What this trial is testing

ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers

Who this might be right for
Advanced MalignancyAdvanced Solid CancersMetastatic Solid Tumors
Adcytherix SAS 290
Testing effectiveness (Phase 2)Ended earlyNCT01990352
What this trial is testing

Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy

Who this might be right for
Breast Cancer
University of Arizona 24
Testing effectiveness (Phase 2)UnknownNCT00839111
What this trial is testing

Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment

Who this might be right for
Colorectal Neoplasms
Fudan University 43
Testing effectiveness (Phase 2)Study completedNCT00253370
What this trial is testing

Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionMetastatic Gastric CancerAdvanced Unresectable Gastric Cancer
National Cancer Institute (NCI) 44
Not applicableLooking for participantsNCT06531681
What this trial is testing

Precision Radiotherapy for Tumours Using Magnetic Resonance-guided Linear Accelerator (MR-Linac)

Who this might be right for
Overall Response RateOncologyRadiation Toxicity+1 more
The Second Affiliated Hospital of Hainan Medical University 3,000
Testing effectiveness (Phase 2)UnknownNCT04899427
What this trial is testing

Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma

Who this might be right for
Primary Central Nervous System Lymphoma
Peking Union Medical College Hospital 32
Not applicableStudy completedNCT04028479
What this trial is testing

The Registry of Oncology Outcomes Associated With Testing and Treatment

Who this might be right for
AdenocarcinomaAdenocystic CarcinomaAnal Cancer+73 more
Taproot Health 167
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07591831
What this trial is testing

Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant Recurrent Ovarian CancerFallopian Tube CancersEpithelial Ovarian Cancer+1 more
Tianjin Medical University Cancer Institute and Hospital 30
Next Page